Judging Panel

An independent panel of recognised and expert judges, drawn from academia, business and broader related sectors will determine the winners of the Pharma Industry Awards.

Our focus is to deliver a balanced judging assessment from industry leaders who will bring their extensive knowledge, enthusiasm and expertise to the judging process ensuring that the winning entries are truly outstanding and worthy of receiving a trophy.

The panel is carefully selected to ensure the Awards judging process is fair and objective. The judges are bound by a strict confidentiality agreement and are required to declare any conflict of interest in entries over which they deliberate, in which case that entry will be reallocated. The integrity of this process lies at the very heart of all that we do.

A comprehensive judging process has been developed to decide the winners of the Pharma Industry Awards.

If you are interested in joining the judging panel, please email your details to our team: judges@businessriver.com

2024 Judging Panel

Matt Moran (Judging Coordinator)

Independent Consultant,

Matt Moran is the Retired Director of BioPharmaChem Ireland, an industry association within Ibec that represents the biopharmachem sector in Ireland VIEW MORE

David Brayden

University College Dublin, University College Dublin

David Brayden is the Full Professor of Advanced Drug Delivery at University College Dublin. His research is on the oral administration of large molecules. VIEW MORE

John Henchion

VP for Europe, CAI, CAI

John is a 25 year plus industry professional. John is an experienced QP with a decade's experience releasing both commercial and clinical product to market. John holds a hons Degree in Chemistry from Kingston University, London and three post graduate diplomas from Trinity College Dublin and IMI/UCC VIEW MORE

Helena Kelly

Professor Drug Delivery, RCSI University of Medicine and Health Sciences

Pharmacist and academic with a focus on teaching and research in the field of advanced drug delivery systems across a range of disease states, and a particular interest in the potential for drug delivery approaches to improve outcomes in difficult to treat cancers. VIEW MORE